Pfizer Stock News

Pfizer''s vaccine products generate the most revenue, primarily driven by sales of its vaccine against COVID-19.

Chinese health authorities announced that they granted conditional approval for the COVID-19 pill developed by Pfizer (PFE), making it the first oral drug specifically authorized to…

Following the FDA''s issuance of a safety warning regarding JAK inhibitors, the safety committee of the European Medicines Agency initiated a review of these treatments , which are used to treat several chronic inflammatory disorders like rheumatoid arthritis and atopic dermatitis. The EMA''s PRAC said its review was prompted by the final results from a clinical trial of Pfizer Inc''s (NYSE: PFE ) JAK inhibitor Xeljanz (tofacitinib). The results showed that patients taking Xeljanz for rheumatoid arthritis and who were at risk of heart disease were more likely to experience a major cardiovascular … Full story available on Benzinga.com

The FDA has postponed the Advisory Committee meeting scheduled for Pfizer Inc (NASDAQ: PFE ) / BioNTech SE''s (NASDAQ: BNTX ) COVID-19 vaccine in children six months through 4 years of age, initially scheduled for February 15. The decision comes after a preliminary assessment of data submitted by Pfizer / BioNTech to request emergency authorization, and the agency thinks it needed more data before weighing in on approval. The extension allows the FDA time to receive updated data on the two and three-dose regimen, Pfizer said, while … Full story available on Benzinga.com

Pfizer CEO Albert Bourla has admitted that his company created SARC-CoV-2 in their labs for the purposes of developing mRNA jabs rather than use a naturally-occuring coronavirus. Bourla made the stunning admission during a CNBC […] The post Pfizer CEO: We Created COVID-19 in a Lab – Stunning Admission appeared first on News Punch .

TOKYO - Japan has agreed with Pfizer Inc. to purchase an additional 10 million COVID-19 vaccine doses by Mar

TOKYO (Reuters) - Japan''s government said on Monday it has agreed to buy an additional 10 million does of COVID-19 vaccine from Pfizer Inc to be delivered in March. Japan had already contracted to purchase 120 million doses from Pfizer this year. Including the extra shots and acceleration of shipments, Japan will import 46 million Pfizer doses in March to aid in…

WASHINGTON, Feb. 14, 2022 (GLOBE NEWSWIRE) -- The Global Biosimilars Market size is expected to reach USD 103.94 Billion by 2028, exhibiting a Compound Annual Growth Rate (CAGR) of 25.6% during the forecast period. Market growth for Biosimilars is due to the increasing cases of chronic diseases with high demand of biosimilars as they are cost effective. Additionally, regulatory approval as well as other regulations favouring the biosimilars adoption in several countries is a major factor boosting Biosimilars Market. However, complexities in development & manufacturing of the biosimilars coupled with resistance from reference biologic manufacturers, restraining the market growth, states Vantage Market Research, in a report, titled: " Biosimilars Market by Product Class (Monoclonal Antibodies, Recombinant Hormones, Immunomodulators, Anti-Inflammatory Agents), by Application (Blood Disorders, Growth Hormonal Deficiency, Chronic and Autoimmune Disorders, Oncology), by Region (North America, Europe, Asia Pacific, Latin America) - Global Industry Assessment (2016 - 2021) & Forecast (2022 - 2028) ".

The Washington Examiner reports that health officials in New Haven, Connecticut, are calling for hundreds of people to get “revaccinated” against COVID-19. It turns out that the Pfizer COVID vaccines that these individuals received were mishandled and, therefore, possibly no rendered ineffective. What happened? According to a report from the Hartford Courant, a New Haven […] The post Hundreds of Connecticut residents need to be ‘revaccinated’ after Pfizer vaccine mishap first appeared on Conservative Institute .

Fatigue and frustration are setting in two years into the coronavirus outbreak, and a growing chorus of doctors, parents and state officials are calling for an end to school mask mandates. The issue has long divided Americans across the nation, spurring intense debates and demonstrations at school board meetings , propelling legal battles and emerging as a focal point of state elections . But a national conversation around an "offramp" to masking in schools has accelerated in recent days. As the omicron wave recedes , multiple states have taken action to phase out statewide school mask mandates, and a number of high-profile medical professionals have changed their tunes on the matter. One cohort points to increasing access to vaccinations for children and declining COVID-19 cases, hospitalizations and deaths. Another group argues long-term masking puts an outsize burden on kids, with consequences to their mental health and possibly to their development. "You cannot sustain a red-alert, all-hands-on-deck, emergency kind of response indefinitely," said Dr.

Biotech stocks moved back and forth amid some volatility before finishing the week ending Feb. 11 modestly lower, reversing the gains from the previous week. Earnings news flow continued to dominate proceedings, and the week also witnessed presentations at conferences and a couple of initial public offerings. Pfizer, Inc.''s (NYSE: PFE ) fourth-quarter topline growth trailed expectations, exerting downward pressure on the stock. Modular Medical, Inc. (NASDAQ: MODD ) and TC BioPharm (Holdings) plc American Depositary Shares (NASDAQ: TCBP ) debuted on Wall Street following their IPOs. Novavax, Inc. (NASDAQ: NVAX ) came under pressure midweek after a report suggested that the company is lagging very much behind its COVID-19 delivery commitments. Here are the key catalysts that can move stocks in the biotech space in the coming week: Conferences SVB Leerink Global Healthcare Conference (virtual event): Feb. 14-18 17th Congress Of European Crohn''s and Colitis Organization, or ECCO (virtual event): Feb. 16-19 ASCO Genitourinary Cancers Symposium (hybrid event): Feb. 17-19, in Moscone Center, San Francisco, California and online PDUFA Dates The Food and Drug Administration is scheduled to rule on Agios Pharmaceuticals, Inc.''s (NASDAQ: AGIO ) new drug application for mitapivat, its most advanced drug candidate, as a treatment option for pyruvate kinase deficiency.

BREAKING: Pfizer has withdrawn its application to the FDA for authorization on COVID vaccinations for kids under 5, due to not "enough data." pic.twitter.com/z11j9Rv8Oq

BEIJING: China on Saturday said it had given "conditional" approval for Pfizers Covid-19 drug Paxlovid to treat adults with mild to moderate illness and a high risk of developing severe disease.The drug has so far been authorised in about 40 countries including the United States and Israel,

Food and Drug Administration said Friday that they will wait for data from Pfizer before authorization

The post FDA plan to fast-track Pfizer vaccine for kids under 5 fails appeared on BitcoinEthereumNews.com . Parents of children under 5 will have to wait until at least April to get their kids vaccinated against Covid-19, after the Food and Drug Administration and Pfizer this week